Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery

Absci Corporation begins dosing patients in the first human trial of ABS-201, an AI-designed antibody for hair loss, reaching clinic in just 24 months.

Raccontata dacryptobriefing.com